> Procedures > Therapeutic or Preventive Procedure > Antineoplastic Combined Chemotherapy Protocols

Antineoplastic Combined Chemotherapy Protocols

Antineoplastic Combined Chemotherapy Protocols: An AI-driven platform, PubCompare.ai, helps researchers locate the most effective chemotherapy protocols from literature, pre-prints, and patents.
By comparing protocols, PubCompare.ai identifies the optimal combinations to enhance research reproducibility and improve patient outcomes.
Discvoer the power of AI-assisted optimization for your antineoplastic combined chemotherapy research today.

Most cited protocols related to «Antineoplastic Combined Chemotherapy Protocols»

Incorporating Tumor Cavitation in NSCLC Response Assessment

Cited 9 times

Lung cancer is the leading cause of cancer death in the United States and worldwide, accounting for nearly 160,000 deaths per year in the United States [50 (link), 51 ]. Recent investigations of the molecular basis of lung cancer have enabled clinical applications of targeted therapeutic agents, including the EGFR tyrosine kinase inhibitors and antiangiogenic agents, such as vascular EGFR inhibitors [3 (link)–5 (link), 52 (link)]. Tumor cavitation of pulmonary lesions is commonly observed in NSCLC treated with vascular EGFR inhibitors [53 (link), 54 (link)]. Because the cavitary portion of the tumor filled with air does not contribute to the tumor volume, the assessment of tumor burden may be improved by incorporating the cavitation into the measurement. On the basis of these observations, Crabb et al. [54 (link)] proposed an alternate method incorporating cavitation in response assessment for NSCLC treated with vascular EGFR inhibitors. In this method, the central cavity diameter is subtracted from the overall longest diameter of the lesion (Fig. 5). All other details for response assessment are identical to RECIST [54 (link)]. In a retrospective review of 33 patients treated with vascular EGFR inhibitor combined with platinum-based chemotherapy, tumor cavitation was observed in 24% of the patients. However, the alternate method for response assessment resulted in an alteration of response assessment, time to best response, duration of response, and time of disease progression in only a minority of patients compared with RECIST [54 (link)].
More recently, Lee et al. [55 (link)] proposed another set of criteria for NSCLC treated with EGFR tyrosine kinase inhibitors, which include tumor constituents such as solid and ground-glass opacity components, tumor cavitation, and CT attenuation changes. In their analysis of 75 patients with NSCLC treated with EGFR tyrosine kinase inhibitors, the criteria had a statistically significant association with overall survival [55 (link)]. Both criteria remain to be prospectively tested in a larger patient population.

Nishino M., Jagannathan J.P., Krajewski K.M., O'Regan K., Hatabu H., Shapiro G, & Ramaiya N.H. (2012). Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST. Ajr. American Journal of Roentgenology, 198(4), 737-745.

Publication 2012

Angiogenesis Inhibitors Antineoplastic Combined Chemotherapy Protocols Blood Vessel Dental Caries Disease Progression EGFR protein, human inhibitors Lung Cancer Lung Neoplasms Malignant Neoplasms Minority Groups Neoplasms Non-Small Cell Lung Carcinoma Patients Platinum Therapeutics Tumor Burden

Microarray Analysis of Tumor and Metastasis

Cited 5 times

Microarray analyses were applied to tumor and metastasis biopsies from 13 individuals following a randomized and blinded unbalanced design. Additional human normal colon samples (C_A, C_B, C_C), one colon adenocarcinoma sample (C_T) and one normal liver (C_L) tissue sample (Stratagene) were included as calibration controls but were not considered in statistical analyses. Uneven numbers of samples were randomly allocated to each of the engineers who were not aware of sample phenotypes. To assess data reproducibility and minimize dye bias effects, each of the samples was measured four times, twice with Cy3 and twice with Cy5. To ensure robustness and flexibility in data analysis, a reference design was used with a universal reference sample (Stratagene) serving as a baseline for the comparisons of tumor samples. Such a design does not require pre-definition of the subgroups for comparison, allows robust discovery of non-anticipated classes among the samples and is compatible with subsequent additional sampling.
Statistical power (1-β) for t statistics of the experimental design was computed for estimation of false negatives (FNR) and FDRs [99 (link)] as shown in Additional data file 3. This calculation is based on the observation that the gene-specific expression measurements are approximately normally distributed, and takes into account the accepted confidence level (α), the magnitude of the effect measured (Φ), the biological variation (σ) expected in the population investigated, and the size of the groups of samples from individual patients (n1, n2). Statistical comparison was done considering that biopsies collected prior to drug exposure may be subsequently categorized in two groups of chemo-sensitive (complete and partial responses) or resistant (progressive and stable diseases; Additional data file 10) samples in view of the initial response rates of individual patients to combined chemotherapy [11 (link)].

Graudens E., Boulanger V., Mollard C., Mariage-Samson R., Barlet X., Grémy G., Couillault C., Lajémi M., Piatier-Tonneau D., Zaborski P., Eveno E., Auffray C, & Imbeaud S. (2006). Deciphering cellular states of innate tumor drug responses. Genome Biology, 7(3), R19.

Full text: Click here

Publication 2006

Antineoplastic Combined Chemotherapy Protocols Biopharmaceuticals Biopsy Colon Colon Adenocarcinomas Gene Expression Homo sapiens Liver Microarray Analysis Neoplasm Metastasis Neoplasms Patients Pharmaceutical Preparations Phenotype Sensitive Populations Tissues

Sintilimab Plus Chemotherapy for ESCC

Cited 4 times

Every three weeks, all patients received sintilimab or placebo combined with chemotherapy. The chemotherapy regimen was chosen by the investigator: cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil. Sintilimab or placebo was given intravenously at a dose of 3 mg/kg in patients weighing <60 kg or 200 mg in patients weighing ≥60 kg on day 1 of each cycle. Cisplatin (75 mg/m² on day 1 of each cycle) plus paclitaxel (87.5 mg/m² on day 1 and day 8 of cycle 1; 175 mg/m² on day 1 of the other cycles) or 5-fluorouracil (800 mg/m² continuous administration on days 1-5 of each cycle) were also given intravenously. A maximum of six cycles was recommended for chemotherapy. Treatment with sintilimab or placebo was continued until progressive disease, intolerable toxicity, the start of new antitumour treatment, withdrawal of consent, lost to follow-up, death, completion of treatment, or any other reasons determined by the investigators for stopping treatment, whichever occurred first.
Sintilimab or placebo was continued for a maximum of 24 months. Sintilimab or placebo was used alone if chemotherapy was intolerable, or when six cycles of chemotherapy had been given. The choice of chemotherapy regimen (cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil) could not be switched during the study. Appendix 2 provides more details of the study design.
Assessments of the tumours were performed by the investigators according to RECIST version 1.1 at baseline, once every six weeks for 48 weeks, and then once every 12 weeks. Adverse events were assessed up to 90 days after the last dose and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 5.0). Survival was assessed every 60 days during follow-up.
Expression of PD-L1 in fresh or archival tumour sample was assessed during screening at a central laboratory (Covance, Shanghai, China) with the PD-L1 immunohistochemistry 22C3 pharmDx assay (Agilent Technologies, Carpinteria, CA, USA). The combined positive score was defined as the number of PD-L1 staining cells (tumour cells, lymphocytes, and macrophages) divided by the total number of viable tumour cells. The tumour proportion score was defined as the percentage of viable tumour cells showing partial or complete membrane staining.

Lu Z., Wang J., Shu Y., Liu L., Kong L., Yang L., Wang B., Sun G., Ji Y., Cao G., Liu H., Cui T., Li N., Qiu W., Li G., Hou X., Luo H., Xue L., Zhang Y., Yue W., Liu Z., Wang X., Gao S., Pan Y., Galais M.P., Zaanan A., Ma Z., Li H., Wang Y., Shen L., Pan Z., Zhang S., Lin G., Xie Y., Li T., Ren T., Li W., Gu K., Wang S., He W., Xia B., Fan Y., Liang J., Zhao K., Pan H., Xu N., Cheng Y., Gao Q., Sun P., Zang A., Zheng A., Luo Z., Liu T., Ding S., Xu T., Li W., Liu F., Cang S., Wang J., Lin X., Jiang D., Mao R., Ma D., Liu Y., Tao M., Tang Y., Chen X., Chen P., Feng G., Yang Z., Zhang G., Zhang X., Huang Y., Lee F.C., Dean A., El Hajbi F., Ghiringhelli F., Borg C., Tougeron D., Dahan L., Pernot S., Rivera F., Pazo Cid R.A, & Vazquez Rivera M.F. (2022). Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. The BMJ, 377, e068714.

Publication 2022

Antineoplastic Combined Chemotherapy Protocols Biological Assay CD274 protein, human Cells Cisplatin Fluorouracil Immunohistochemistry Lymphocyte Macrophage Neoplasms Paclitaxel Patients Pharmacotherapy Placebos sintilimab Tissue, Membrane TP protocol Treatment Protocols

Head and Neck Cancer Organ Preservation Protocol

Cited 3 times

Eligible participants were recruited through a tertiary head and neck cancer center in Baltimore, Maryland, USA, beginning in December 2004, closing to recruitment in May 2011 and ending data collection in August 2013. Following Institutional Review Board approval, eligible participants were identified at a weekly head and neck tumor board conference by the speech pathologist. Participants were required to be at least 21 years of age with biopsy-proven Stage III or IV squamous cell carcinoma of the oral, oropharynx, pharynx or larynx regions only to meet inclusion criteria. Only those participants who were scheduled to receive curative non-surgical treatment at the institution, and were planned for completion of combined chemotherapy and hyperfractionated radiation therapy adhering with the institution’s organ preservation protocol for Stage III-IV HNC (using traditional 3D planning techniques with concomitant cisplatin and 5-fluorouracil) were recruited in the first few years. In the final years of recruitment, due to a change within the clinic away from this protocol, only those then planned to receive the modified organ preservation protocol for Stage III-IV HNC (using IMRT inverse planning technology and delivery used image guidance with concomitant cisplatin) were recruited. Recruitment was confined to these protocols only to minimize variability from different treatment regimes.
In addition, the physicians assessed the participants’ ability to perform ordinary tasks using the Karnofsky Performance Status Scale [32 (link)], with a score of 50% or more required for participation. Participants were excluded if there was evidence of distant disease, previous radiation therapy, major psychiatric illness, severe dysphagia before treatment requiring parenteral nutrition, or any concurrent illness that, in the investigator’s judgment, might increase the risk associated with participation in the study.

Messing B.P., Ward E.C., Lazarus C.L., Kim M., Zhou X., Silinonte J., Gold D., Harrer K., Ulmer K., Merritt S., Neuner G., Levine M., Blanco R., Saunders J, & Califano J. (2017). Prophylactic Swallow Therapy for Patients with Head and Neck Cancer Undergoing Chemoradiotherapy: A Randomized Trial. Dysphagia, 32(4), 487-500.

Full text: Click here

Publication 2017

Antineoplastic Combined Chemotherapy Protocols Biopsy Cancer of Head and Neck Cisplatin Conferences Deglutition Disorders Ethics Committees, Research Fluorouracil Head and Neck Neoplasms Larynx Mental Disorders Obstetric Delivery Operative Surgical Procedures Organ Preservation Oropharyngeal Squamous Cell Carcinoma Parenteral Nutrition Pathologists Pharynx Physicians Radiotherapy Radiotherapy, Intensity-Modulated Speech

First-Line Platinum-Based Chemotherapy in NSCLC

Cited 2 times

The study population consists of NSCLC patients (stage II–IV) undergoing first‐line platinum‐based chemotherapy as part of routine patient care.
Inclusion criteria: (i) Older than 18 years of age; (ii) radiologically‐confirmed NSCLC (stage II–IV); and (iii) first‐line treatment with platinum‐based (cisplatin or carboplatin) chemotherapy or chemoradiotherapy (according to the contemporary ESMO Clinical Practice Guidelines).⁴, ⁵ Patients are platinum‐based chemotherapy‐naïve and treatment is planned or has been initiated.
Exclusion criteria: (i) Cognitive impairment; and (ii) unable to read and write Dutch.
All patients receive at least one cycle of a platinum‐agent combined with a chemotherapeutic agent (eg, etoposide, gemcitabine, pemetrexed, paclitaxel), targeted therapy (bevacizumab) and/or immunotherapy (eg, atezolizumab, nivolumab, pembrolizumab), depending on tumor histology and patient characteristics. Radiotherapy can be either sequential or concurrent, according to the physician's choice. Patients can enroll in the study prior to initiation of chemotherapy or after chemotherapy has been initiated. All treatment procedures (ie, diagnostic work‐up, laboratory tests) will be according to local clinical practice for routine patient care. The end of study is the date of the end of follow‐up of the last included patient.

de Jong C., Herder G.J, & Deneer V.H. (2020). Genetic variants as predictors of toxicity and response in patients with non‐small cell lung cancer undergoing first‐line platinum‐based chemotherapy: Design of the multicenter PGxLUNG study. Thoracic Cancer, 11(12), 3634-3640.

Full text: Click here

Publication 2020

Antineoplastic Combined Chemotherapy Protocols atezolizumab Bevacizumab Carboplatin Chemoradiotherapy Cisplatin Diagnosis Disorders, Cognitive Etoposide Gemcitabine Immunotherapy Neoplasms Nivolumab Non-Small Cell Lung Carcinoma Paclitaxel Patients pembrolizumab Pharmacotherapy Platinum Radiotherapy

Most recents protocols related to «Antineoplastic Combined Chemotherapy Protocols»

Neoadjuvant Chemoimmunotherapy for Lung Cancer

All patients received PD-1/PD-L1 immune checkpoint inhibitors combined with platinum-based doublet chemotherapy as neoadjuvant chemoimmunotherapy. Chemoimmunotherapy drugs were given on the first day of each treatment cycle (21 days per cycle). A standard staging evaluation was performed before and after neoadjuvant chemoimmunotherapy, including a computed tomography (CT) scan (11 (link)); 18-F-fluorodeoxyglucose positron emission tomography/CT scan; magnetic resonance imaging or CT for the brain; and a bronchoscopy examination. All patients received 18-F-fluorodeoxyglucose positron emission tomography/CT scan to assess the presence of mediastinal involvement before and after neoadjuvant chemoimmunotherapy. Surgery was planned 3–7 weeks after the first day of the last treatment cycle. If there were progressive M1 or N3 metastasis after neoadjuvant chemoimmunotherapy, patients would continue medical therapy and be excluded from this study. The type of resection for the primary tumor was determined according to standard institutional procedures, including lobectomy, bronchial or vascular sleeve lobectomy, bilobectomy, and pneumonectomy. Systematic lymphadenectomy was performed in every patient. Decisions of conversion to thoracotomy were made by surgeons during operation whenever they felt necessary. Pathological responses and yield pathologic stage (yp-stage) were determined by the Department of Pathology according to resected samples.
Patients were divided into the VATS or RATS groups according to the initial surgery approach. Surgery approach was determined by patients’ will. All surgeries were performed by surgeons with extensive experience. VATS was performed in a two-port or three-port approach liberally. RATS was performed using the Da Vinci Xi surgery system (Intuitive Surgical, Inc., Mountain View, CA, USA), using the three-arm method. Patients without viable tumor cells in resected lymph nodes and primary lung cancer were defined as pCR, while less than 10% of viable tumor cells were defined as MPR, and more than 10% were defined as an incomplete pathological response (IPR) (12 (link)).

Zeng J., Yi B., Chang R., Chen Y., Yu Z, & Gao Y. (2023). Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Frontiers in Oncology, 13, 1134713.

Full text: Click here

Publication 2023

Antineoplastic Combined Chemotherapy Protocols Blood Vessel Brain Bronchi Bronchoscopy CD274 protein, human Cells F18, Fluorodeoxyglucose Feelings Immune Checkpoint Inhibitors Lung Cancer Lymph Node Excision Mediastinum Neoadjuvant Therapy Neoplasm Metastasis Neoplasms Operative Surgical Procedures Patients Pharmaceutical Preparations Platinum Pneumonectomy Radionuclide Imaging Rattus norvegicus Scan, CT PET Surgeons Therapeutics Thoracic Surgery, Video-Assisted Thoracotomy X-Ray Computed Tomography

Personalized Treatment for Endometrial Cancer

Treatment in experimental arm is based on molecular classification. Participants with POLEmut subtype, accounting for approximately 10% of all EEC and having quite a good prognosis [1 (link)], will be observed. An estimated 70% of patients with the MMRd or NSMP subtype will receive VBT (either 3 fractions of 7 Gy to 5 mm depth or 5 fractions of 6 Gy to the surface). Approximately 20% will have a p53abn profile and receive combined chemotherapy and radiotherapy (CTRT), with 4 adjuvant cycles of carboplatin and paclitaxel, followed by external beam pelvic radiotherapy (EBRT, 45–50 Gy) (Fig. 1).
The preferred treatment for the standard arm is recommended in accordance with the NCCN guidelines version 1 (2022) according to the clinicopathological risk factors [4 ]. Patients with IR (stage IA grade 3 or stage IB grade 1–2) will receive adjuvant VBT (3 fractions of 7 Gy or 5 fractions of 6 Gy). Patients with HIR (stage IB grade 3 or stage II) will receive adjuvant EBRT and/or VBT. The suggested dose for EBRT is 45-50 Gy in daily fractions of 1.8 Gy over 25–28 fractions, 5 times a week. The total dose for EBRT and VBT is 65 Gy.
Patients will be clinically evaluated during alternating follow-up visits with their gynecologist and radiation oncologist every 3 months for the first year, every 6 months for the next two years, and each year for the 4th and 5th years. Pelvic examination and serum CA125 test will be done at each visit. CT scan of abdomen, pelvis and chest will be done every six months. A comprehensive assessment will be performed when recurrence or metastasis is suspected, and treatment with curative intention will be initiated when necessary.

Li Y., Zhu C., Xie H., Chen Y., Lv W., Xie X, & Wang X. (2023). Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT). Journal of Gynecologic Oncology, 34(2), e37.

Publication 2023

Abdomen Antineoplastic Combined Chemotherapy Protocols CA-125 Antigen Carboplatin Chest Gynecologist Neoplasm Metastasis Paclitaxel Patients Pelvic Examination Pelvis Pharmaceutical Adjuvants Prognosis Radiation Oncologists Radiotherapy Recurrence Serum Therapies, Investigational X-Ray Computed Tomography

Nivolumab Combination Therapy for Esophageal Cancer

Patients will be randomly assigned in a 2:1 allocation ratio to receive nivolumab combined with chemotherapy followed by MIE (arm A, nIT + nCT group) or placebo + nCT followed by MIE (arm B, nCT group) and were stratified according to coordinating centers. Randomization will be assigned by the central dynamic, computer-generated random system. The stratification factors include age, tumor location and clinical staging. The research center will generate assignments in the random system online after enrollment.
The study will use an internally blinded double-blind approach. Nivolumab and normal saline were in the same package, and the corresponding labels were prepared and affixed on site to maintain blindness. Subjects, investigators and sponsor staff who participated in subject treatment or clinical evaluation were unaware of the assignments. Only the open-label pharmacist/nurse will obtain each subject’s study identification number and study drug assignment from the central randomization system and prepare the drugs.

Yin J., Lin S., Fang Y., Jiao H., Chen Z., Tang H., Gu J., Zhang S., Sun L., Li Y., Han Y., Chen Q., Chen H., Li Z, & Tan L. (2023). Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial). Journal of Thoracic Disease, 15(2), 718-730.

Publication 2023

Antineoplastic Combined Chemotherapy Protocols Blindness Neoplasms by Site Nivolumab Normal Saline Nurses Patients Pharmaceutical Preparations Placebos

Retrospective Analysis of Thoracic ESCC

A retrospective analysis was performed on thoracic ESCC patients who received surgery in Tangdu Hospital affiliated to Fourth Military Medical University from April 2019 to December 2020. The 8th version of American Joint Committee on Cancer was used for preoperative and postoperative staging of the patients.^{[11 (link)]} Inclusion criteria as follows: Thoracic ESCC received Mckeown resection; Lymph node dissection ≥ 2.0 field; Preoperative albumin-binding paclitaxel combined with nedaplatin chemotherapy for 2 to 3 cycles, and; Postoperative TRG analysis was performed.

Chen J., Zhu J., Zhang Y., Wang W., Xia Y., Zhao J, & Jiang T. (2023). Efficacy of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant therapy for esophageal squamous cell carcinoma: A single-center retrospective observational study. Medicine, 102(9), e33157.

Full text: Click here

Publication 2023

Antineoplastic Combined Chemotherapy Protocols Joints Lymph Node Excision Malignant Neoplasms Military Personnel nedaplatin Operative Surgical Procedures Paclitaxel, Albumin-Bound Patients

Irinotecan Chemotherapy Regimens and Neutropenia

The medical records of 1312 patients receiving irinotecan based chemotherapy at Renmin Hospital of Wuhan University from May 2014 to May 2019 were collected. A retrospective analysis of 612 patients was finalized according to the inclusion and exclusion criteria below.
The inclusion criteria were as follows: Patients ≥ 18 years old; normal range of white blood cell (WBC) and absolute neutrophil count (ANC) tests at baseline before chemotherapy; conduction of follow-up laboratory data adequate for assessing neutropenia; and reasonable prescription of irinotecan. The exclusive criteria were: liver and kidney trans-plantation prior to the onset of neutropenia; neutropenia induced by other drugs before chemotherapy; and disease of blood and hematopoietic system such as leukemia, thrombocytopenic purpura, and so on.
The chemotherapy regimens and dose of irinotecan in this study: irinotecan alone (125mg/m², d1, d8, d15, and d22, repeated every 6 weeks; 350mg/m², dL, repeated every 3 weeks), irinotecan plus 5-Fluorouracil (180mg/m², dL, repeated every 2 weeks), irinotecan plus capecitabine (250 mg/m², dL, repeated every 3 weeks), irinotecan plus cisplatin (60mg/m², dL, d8, and d15, repeated every 4 weeks; 65mg/m², dL, d8, and d15, repeated every 3 weeks), irinotecan plus lobaplatin (80 mg/m² or 90mg/m², dL, d8, repeated every 3 weeks), irinotecan plus nedaplatin (60mg/m² or 65mg/m², dL, d8, repeated every 3 weeks), irinotecan plus bevacizumab (125mg/m², dL, repeated every 2 weeks) and irinotecan plus raltitrexed (150 or 180mg/m², dL, repeated every 2 weeks; 240mg/m², dL, repeated every 3 weeks). Dose and schedule of irinotecan was modified according to patient age, medical condition and the combination with other anticancer drugs by each attending physician decision.

Zhang S., Yang J., Zhan H., Yang B., Rong P., Luo Y., Shi C., Chen Y, & Yang J. (2023). Incidence and non-genetic risk factors of irinotecan-induced severe neutropenia in Chinese adult inpatients. Medicine, 102(9), e33005.

Publication 2023

Antineoplastic Combined Chemotherapy Protocols Bevacizumab Capecitabine Cisplatin Electric Conductivity Fluorouracil Hematological Disease Hematopoietic System Irinotecan Kidney Leukemia Leukocytes Leukopenia Liver lobaplatin nedaplatin Neutrophil Patients Pharmaceutical Preparations Pharmacotherapy Physicians Thrombocytopenic Purpura Treatment Protocols

Top products related to «Antineoplastic Combined Chemotherapy Protocols»

Fetal bovine serum (fbs) by Thermo Fisher Scientific

Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal

Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.

Calcusyn software by Biosoft

Sourced in United Kingdom, United States, Macao

CalcuSyn is a software application designed for dose-effect analysis. It provides tools for calculating the combined effects of multiple drugs or agents on a given biological system.

Penicillin g by Thermo Fisher Scientific

Sourced in United States, United Kingdom, Canada, Germany, China, France, Japan, Israel, Italy, Australia, Switzerland, Argentina, New Zealand, Sweden, Austria

Penicillin G is a broad-spectrum antibiotic used in various laboratory and research applications. It is a naturally occurring compound produced by the Penicillium fungus. Penicillin G is effective against a wide range of Gram-positive and some Gram-negative bacteria.

Ethos therapy by Agilent Technologies

Sourced in United States

The Ethos Therapy is a laboratory equipment product offered by Agilent Technologies. It is designed to perform microwave-assisted sample preparation for various analytical applications. The core function of the Ethos Therapy is to facilitate efficient sample digestion and extraction processes.

Spss version 18 by IBM

Sourced in United States, United Kingdom, Japan, Thailand, China, Italy, Germany

SPSS version 18.0 is a statistical software package developed by IBM. It provides data management, analysis, and reporting capabilities. The core function of SPSS is to assist in the analysis of data and presentation of results.

Bovine serum albumin (bsa) by Merck Group

Sourced in United States, Germany, United Kingdom, China, Italy, Japan, France, Sao Tome and Principe, Canada, Macao, Spain, Switzerland, Australia, India, Israel, Belgium, Poland, Sweden, Denmark, Ireland, Hungary, Netherlands, Czechia, Brazil, Austria, Singapore, Portugal, Panama, Chile, Senegal, Morocco, Slovenia, New Zealand, Finland, Thailand, Uruguay, Argentina, Saudi Arabia, Romania, Greece, Mexico

Bovine serum albumin (BSA) is a common laboratory reagent derived from bovine blood plasma. It is a protein that serves as a stabilizer and blocking agent in various biochemical and immunological applications. BSA is widely used to maintain the activity and solubility of enzymes, proteins, and other biomolecules in experimental settings.

Spectramax m2e by Molecular Devices

Sourced in United States, United Kingdom, Germany, Japan, France, Canada

The SpectraMax M2e is a multi-mode microplate reader that can perform absorbance, fluorescence, and luminescence measurements. It is designed for a wide range of applications in life science research and drug discovery.

Discovery 750w by GE Healthcare

Sourced in United States

The Discovery 750w is a versatile lab equipment product from GE Healthcare. It is designed to perform a range of analytical tasks within the laboratory environment. The core function of the Discovery 750w is to provide reliable and accurate measurements and analysis of samples.

D2650 by Merck Group

Sourced in United States, Germany, Switzerland, United Kingdom, China, France

The D2650 is a laboratory instrument manufactured by Merck Group. It is designed to perform high-precision measurements and analyses in scientific research and testing environments. The core function of the D2650 is to provide accurate and reliable data, without interpretation or extrapolation beyond its intended use.

Stata 14 by StataCorp

Sourced in United States, Denmark, United Kingdom, Belgium, Japan, Austria, China

Stata 14 is a comprehensive statistical software package that provides a wide range of data analysis and management tools. It is designed to help users organize, analyze, and visualize data effectively. Stata 14 offers a user-friendly interface, advanced statistical methods, and powerful programming capabilities.

More about "Antineoplastic Combined Chemotherapy Protocols"

Antineoplastic Combined Chemotherapy Protocols refer to the optimization and comparison of different cancer treatment regimens that combine multiple chemotherapeutic agents.
These protocols are crucial in enhancing the effectiveness and reproducibility of cancer research, as well as improving patient outcomes.
PubCompare.ai is an AI-driven platform that helps researchers locate the most effective chemotherapy protocols from literature, preprints, and patents.
By utilizing advanced algorithms, the platform compares various protocols and identifies the optimal combinations to enhance research reproducibility and improve patient outcomes.
Synonyms and related terms include: Anticancer Drug Combinations, Multi-Agent Chemotherapy, Combination Chemotherapy, Antineoplastic Drug Combinations, and Chemothereapy Regimens.
Abbreviations commonly used in this context include: ACCP (Antineoplastic Combined Chemotherapy Protocols), CCRT (Concurrent Chemoradiotherapy), and FOLFIRINOX (Folinic Acid, Fluorouracil, Irinotecan, and Oxaliplatin).
Key subtopics within Antineoplastic Combined Chemotherapy Protocols include: - Synergistic drug interactions - Dose optimization - Toxicity management - Biomarker-driven protocols - Combination with targeted therapies - Combination with immunotherapy FBS (Fetal Bovine Serum), CalcuSyn software, Penicillin G, Ethos Thereapy, SPSS version 18.0, Bovine serum albumin, SpectraMax M2e, Discovery 750w, D2650, and Stata 14 are some of the tools and techniques used in the research and development of Antineoplastic Combined Chemotherapy Protocols.
Discvoer the power of AI-assisted optimization for your antineoplastic combined chemotherapy research today with PubCompare.ai, and unlock new possibilities in cancer treatment.